GlaxoSmithKline News and Research

RSS

Google Eyes Wider Healthcare Footprint With Tech-Focused Calico

...

19 Sep 2013

GSK Returns Vercirnon Rights To Chemocentryx After Phase III Flop

...

19 Sep 2013

GSK Returns Vercirnon Rights To Chemocentryx After Phase III Flop

...

18 Sep 2013

Pertussis incidence among older adults may be under-recognized, study finds

The incidence of pertussis among U.S. adults 50 and older may be greatly under-reported and under-recognized, according to findings from a study conducted by GlaxoSmithKline researchers who analyzed approximately 48 million cases of cough-related illness in the U.S. between 2006 and 2010.

13 Sep 2013

2D Barcoding of U.S. vaccines: an interview with Dr. Leonard Friedland, VP, Director, Scientific Affairs and Public Health, GSK Vaccines North America

2D barcodes contain product identification, lot number, and expiration date. Linear barcodes only contain product identification information.

10 Sep 2013

Scientists provide proof of principle for drug-based treatment of acute pancreatitis

Scientists have for the first time provided proof of principle for a drug-based treatment of acute pancreatitis - a disease which is often alcohol-related and for which currently there is no treatment.

4 Sep 2013

Pazopanib drug shows improved quality of life and safety in metastatic kidney cancer patients

Two oral targeted drugs approved for metastatic kidney cancer worked equally well, but one proved superior in tolerability, according to results of a large international clinical trial led by researchers at Dana-Farber Cancer Institute.

22 Aug 2013

Second GSK intramuscular quadrivalent influenza vaccine approved by the FDA

GlaxoSmithKline plc [LSE/NYSE: GSK] announced that the U.S. Food and Drug Administration (FDA) has approved FLULAVAL® QUADRIVALENT (Influenza Virus Vaccine) for the active immunization of persons three years of age and older to help prevent disease caused by seasonal influenza (flu) virus subtypes A and B contained in the vaccine.

19 Aug 2013

ASH announces 12 recipients of its second round of ASH Bridge Grants

As federal funding cuts continue to jeopardize the progress of biomedical research, the American Society of Hematology (ASH), the world's largest professional organization dedicated to the causes and treatments of blood disorders, today announced the 12 recipients of its second round of ASH Bridge Grants.

16 Aug 2013

FDA: New drug Tivicay approved to treat HIV-1 infection

The U.S. Food and Drug Administration today approved Tivicay (dolutegravir), a new drug to treat HIV-1 infection. Tivicay is an integrase strand transfer inhibitor that interferes with one of the enzymes necessary for HIV to multiply.

13 Aug 2013

Novartis earns global CEO Cancer Gold Standard accreditation

Novartis International AG, a multinational healthcare company headquartered in Basel, Switzerland, is the first company to earn global CEO Cancer Gold Standard accreditation. Their commitment to workplace wellness reaches across the globe to positively affect the lives of all their employees.

8 Aug 2013

GSK gets green light from FDA to ship Fluarix Quadrivalent influenza vaccine to healthcare providers

GlaxoSmithKline announced today it has received U.S. Food and Drug Administration approval to start shipping 2013-2014 FLUARIX QUADRIVALENT (Influenza Virus Vaccine) to CDC distribution centers and U.S. healthcare providers. This is the first season that vaccines protecting against more than three strains of influenza (flu) will be commercially available.

6 Aug 2013

Protein linked to learning induces cocaine addiction, say researchers

A team of researchers says it has solved the longstanding puzzle of why a key protein linked to learning is also needed to become addicted to cocaine. Results of the study, published in the Aug. 1 issue of the journal Cell, describe how the learning-related protein works with other proteins to forge new pathways in the brain in response to a drug-induced rush of the “pleasure” molecule dopamine.

2 Aug 2013

GlaxoSmithKline receives CHMP positive opinion for REVOLADE

Ligand Pharmaceuticals Incorporated partner GlaxoSmithKline announced that today, the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion recommending marketing authorization for GSK's REVOLADE (eltrombopag) as a treatment for low platelet counts (thrombocytopenia) in adult patients with chronic hepatitis C infection, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy

26 Jul 2013

Compliance leaders give insight and thoughts in new ebook

Regulatory non compliance costs the pharma industry billions in fines, audits and much more each year. To avoid these fines and bad reputation pharma companies rely heavily on their compliance teams, who provide oversight from R&D to the very end of a product cycle.

26 Jul 2013

Scientists reveal new images of how white blood immune cells attack tumours, viral infections

Scientists from The University of Manchester have revealed new images which provide the clearest picture yet of how white blood immune cells attack viral infections and tumours.

From The University of Manchester 24 Jul 2013

Actavis’ Lamictal ODT drug receives FDA approval for treatment of epilepsy and bipolar disorder

Actavis, Inc. (NYSE: ACT) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for Lamotrigine Orally Disintegrating Tablets, 25 mg, 50 mg, 100 mg and 200 mg, a generic equivalent to GlaxoSmithKline's Lamictal® ODT.

16 Jul 2013

London research fellow says clinical study reports and trial results should be shared publicly

Ben Goldacre, research fellow at the London School of Hygiene and Tropical Medicine, says we need all the evidence to make informed decisions about medicines.

12 Jul 2013

Brisdelle receives FDA approval to treat hot flashes associated with menopause

The U.S. Food and Drug Administration today approved Brisdelle (paroxetine) to treat moderate to severe hot flashes (vasomotor symptoms) associated with menopause. Brisdelle, which contains the selective serotonin reuptake inhibitor paroxetine mesylate, is currently the only non-hormonal treatment for hot flashes approved by the FDA.

29 Jun 2013

NIH awards $12.7M to research groups to explore new treatments for patients in eight disease areas

The National Institutes of Health has awarded $12.7 million to match nine academic research groups with a selection of pharmaceutical industry compounds to explore new treatments for patients in eight disease areas, including Alzheimer's disease, Duchenne muscular dystrophy and schizophrenia.

19 Jun 2013

GlaxoSmithKline News and Research

Google Eyes Wider Healthcare Footprint With Tech-Focused Calico

GSK Returns Vercirnon Rights To Chemocentryx After Phase III Flop

GSK Returns Vercirnon Rights To Chemocentryx After Phase III Flop

Pertussis incidence among older adults may be under-recognized, study finds

2D Barcoding of U.S. vaccines: an interview with Dr. Leonard Friedland, VP, Director, Scientific Affairs and Public Health, GSK Vaccines North America

Scientists provide proof of principle for drug-based treatment of acute pancreatitis

Pazopanib drug shows improved quality of life and safety in metastatic kidney cancer patients

Second GSK intramuscular quadrivalent influenza vaccine approved by the FDA

ASH announces 12 recipients of its second round of ASH Bridge Grants

FDA: New drug Tivicay approved to treat HIV-1 infection

Novartis earns global CEO Cancer Gold Standard accreditation

GSK gets green light from FDA to ship Fluarix Quadrivalent influenza vaccine to healthcare providers

Protein linked to learning induces cocaine addiction, say researchers

GlaxoSmithKline receives CHMP positive opinion for REVOLADE

Compliance leaders give insight and thoughts in new ebook

Scientists reveal new images of how white blood immune cells attack tumours, viral infections

Actavis’ Lamictal ODT drug receives FDA approval for treatment of epilepsy and bipolar disorder

London research fellow says clinical study reports and trial results should be shared publicly

Brisdelle receives FDA approval to treat hot flashes associated with menopause

NIH awards $12.7M to research groups to explore new treatments for patients in eight disease areas

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News